These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 28214288)

  • 1. An Accelerator Mass Spectrometry-Enabled Microtracer Study to Evaluate the First-Pass Effect on the Absorption of YH4808.
    Kim A; Yu BY; Dueker SR; Shin KH; Kim HS; Ahn H; Cho JY; Yu KS; Jang IJ; Lee H
    Clin Pharmacol Ther; 2017 Sep; 102(3):537-546. PubMed ID: 28214288
    [No Abstract]   [Full Text] [Related]  

  • 2. An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects.
    Harrell AW; Wilson R; Man YL; Riddell K; Jarvis E; Young G; Chambers R; Crossman L; Georgiou A; Pereira A; Kenworthy D; Beaumont C; Marotti M; Wilkes D; Hessel EM; Fahy WA
    Drug Metab Dispos; 2019 Dec; 47(12):1457-1468. PubMed ID: 31649125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding value through accelerator mass spectrometry-enabled first in human studies.
    Seymour MA
    J Labelled Comp Radiopharm; 2016 Dec; 59(14):640-647. PubMed ID: 27444819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A physiologically-based pharmacokinetic model adequately predicted the human pharmacokinetic profiles of YH4808, a novel K
    Lee HA; Lee KR; Jang SB; Chung SY; Yu KS; Lee H
    Eur J Pharm Sci; 2019 Mar; 130():1-10. PubMed ID: 30641142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerator MS: its role as a frontline bioanalytical technique.
    Seymour MA
    Bioanalysis; 2011 Dec; 3(24):2817-23. PubMed ID: 22185281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.
    Sarapa N; Hsyu PH; Lappin G; Garner RC
    J Clin Pharmacol; 2005 Oct; 45(10):1198-205. PubMed ID: 16172185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
    Miyaji Y; Ishizuka T; Kawai K; Hamabe Y; Miyaoka T; Oh-hara T; Ikeda T; Kurihara A
    Drug Metab Pharmacokinet; 2009; 24(2):130-8. PubMed ID: 19430168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay.
    Jiang H; Zeng J; Li W; Bifano M; Gu H; Titsch C; Easter J; Burrell R; Kandoussi H; Aubry AF; Arnold ME
    Anal Chem; 2012 Nov; 84(22):10031-7. PubMed ID: 23106420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population PK-PD model of YH4808, a novel P-CAB, and intragastric pH that incorporated negative feedback by increased intragastric pH onto the systemic exposure to YH4808.
    Chung TK; Lee HA; Lee KR; Jang SB; Yu KS; Lee H
    CPT Pharmacometrics Syst Pharmacol; 2022 Sep; 11(9):1223-1233. PubMed ID: 35748058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mini-Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study.
    Spracklin DK; Chen D; Bergman AJ; Callegari E; Obach RS
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):428-434. PubMed ID: 32562380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).
    Annes WF; Long A; Witcher JW; Ayan-Oshodi MA; Knadler MP; Zhang W; Mitchell MI; Cornelissen K; Hall SD
    J Pharm Sci; 2015 Jan; 104(1):207-14. PubMed ID: 25382826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.
    Xu XS; Dueker SR; Christopher LJ; Lohstroh PN; Keung CF; Cao KK; Bonacorsi SJ; Cojocaru L; Shen JX; Humphreys WG; Stouffer B; Arnold ME
    Bioanalysis; 2012 Aug; 4(15):1855-70. PubMed ID: 22943617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics.
    Lappin G; Stevens L
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1021-33. PubMed ID: 18680438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies.
    Gao L; Li J; Kasserra C; Song Q; Arjomand A; Hesk D; Chowdhury SK
    Anal Chem; 2011 Jul; 83(14):5607-16. PubMed ID: 21627104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic analysis of 14C-ursodiol in newborn infants using accelerator mass spectrometry.
    Gordi T; Baillie R; Vuong le T; Abidi S; Dueker S; Vasquez H; Pegis P; Hopper AO; Power GG; Blood AB
    J Clin Pharmacol; 2014 Sep; 54(9):1031-7. PubMed ID: 24805288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Brian Houston J; Oosterhuis B; Bjerrum OJ; Grynkiewicz G; Alder J; Rowland M; Garner C
    Eur J Pharm Sci; 2011 Jun; 43(3):141-50. PubMed ID: 21540108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study of salvianolic acid A in beagle dog after oral administration by a liquid chromatography-mass spectrometry method: a study on bioavailability and dose proportionality.
    Sun J; Zhang L; Song J; Tian S; Huang C; Feng Z; Lv Y; Du G
    J Ethnopharmacol; 2013 Jul; 148(2):617-23. PubMed ID: 23707334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [
    Guerini E; Schadt S; Greig G; Haas R; Husser C; Zell M; Funk C; Hartung T; Gloge A; Mallalieu NL
    Xenobiotica; 2017 Feb; 47(2):144-153. PubMed ID: 27123695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Assessment of the Oral Bioavailability of Three Ca-Channel Blockers Using a Cassette-Microdose Study: A New Strategy for Streamlining Oral Drug Development.
    Yamashita S; Kataoka M; Suzaki Y; Imai H; Morimoto T; Ohashi K; Inano A; Togashi K; Mutaguchi K; Sugiyama Y
    J Pharm Sci; 2015 Sep; 104(9):3154-61. PubMed ID: 26037531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synthesis of [(14) C]AZD5122. Incorporation of an IV (14) C-microtracer dose into a first in human study to determine the absolute oral bioavailability of AZD5122.
    Hickey MJ; Allen PH; Kingston LP; Wilkinson DJ
    J Labelled Comp Radiopharm; 2016 May; 59(6):245-9. PubMed ID: 27169760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.